Full-Year 2025 Financial Results
Access all the information about Grifols' FY25 Financial Results.
Showing 252 search results
Grifols reports revenues of EUR 7,524m, up 7%, and more than doubles Group profit to EUR 402m
Grifols Welcomes Moody’s Ratings’ Upgrade to B1 with Stable Outlook
Grifols receives US FDA approval for new fibrinogen concentrate, FESILTYTM (fibrinogen, human-chmt)
Grifols Welcomes S&P Global Ratings’ Upgrade to ‘BB-’ with Stable Outlook
Grifols obtains approval from the European Medicines Agency for the entire value chain of Grifols Egypt
Egypt achieves self-sufficiency in plasma-derived medicines thanks to Grifols
Publications
Links to our latest financial and sustainability reports and other recent publications.
Financial Report
Explore our last financial and earnings annual report.
Sustainability Report
Integrated and Sustainability Annual Report.
Position Paper
The differential value of plasma-derived medicinal products (PDMPs).
Press Kit
Explore our Press Kit to find key facts and figures on Grifols.
Media Contacts
If you're a journalist or media professional with a question, contact our media relations team.